- Investing Ideas
- U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
90
Companies which are potentially undervalued and in an acceptable financial position.
90 companies
Zevra Therapeutics
Market Cap: US$595.3m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.05
7D
2.4%
1Y
25.6%
ADMA Biologics
Market Cap: US$2.4b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$10.31
7D
-5.7%
1Y
-56.5%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.49
7D
0.3%
1Y
52.4%
CorMedix
Market Cap: US$611.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.90
7D
1.0%
1Y
-12.5%
Bausch Health Companies
Market Cap: US$2.1b
Operates as a diversified specialty pharmaceutical and medical device company.
BHC
US$5.53
7D
-0.9%
1Y
12.2%
Regeneron Pharmaceuticals
Market Cap: US$71.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
REGN
US$709.21
7D
-4.7%
1Y
17.5%
CareDx
Market Cap: US$1.1b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$20.96
7D
-4.1%
1Y
38.2%
Elanco Animal Health
Market Cap: US$11.2b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.51
7D
1.9%
1Y
133.3%
Supernus Pharmaceuticals
Market Cap: US$2.8b
A biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$48.63
7D
-1.7%
1Y
50.1%
Ardelyx
Market Cap: US$1.7b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.30
7D
21.9%
1Y
95.4%
Journey Medical
Market Cap: US$141.8m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.12
7D
-2.7%
1Y
-25.5%
Fennec Pharmaceuticals
Market Cap: US$225.5m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.65
7D
-2.9%
1Y
5.9%
Perrigo
Market Cap: US$1.6b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$11.39
7D
-0.9%
1Y
-54.9%
Exagen
Market Cap: US$73.6m
Designs, develops, and commercializes various testing products under the AVISE brand in the United States.
XGN
US$3.10
7D
13.1%
1Y
-50.4%
Exelixis
Market Cap: US$11.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.17
7D
-1.1%
1Y
10.9%
Viatris
Market Cap: US$17.5b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.20
7D
2.6%
1Y
76.9%
Amphastar Pharmaceuticals
Market Cap: US$974.4m
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
AMPH
US$22.74
7D
5.0%
1Y
-9.5%
Vanda Pharmaceuticals
Market Cap: US$420.9m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$7.56
7D
11.3%
1Y
64.7%
ACADIA Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.19
7D
-0.5%
1Y
46.6%
Qiagen
Market Cap: US$7.1b
Provides sample to insight solutions that transform biological samples into molecular insights worldwide.
QGEN
US$33.96
7D
-10.8%
1Y
-24.6%
TG Therapeutics
Market Cap: US$5.0b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$35.71
7D
0.9%
1Y
-5.2%
Protara Therapeutics
Market Cap: US$287.7m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$5.45
7D
9.2%
1Y
60.8%
Pacira BioSciences
Market Cap: US$961.7m
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
PCRX
US$24.69
7D
-3.4%
1Y
-4.3%
Pelthos Therapeutics
Market Cap: US$83.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$24.82
7D
0.2%
1Y
108.6%
Abeona Therapeutics
Market Cap: US$338.2m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.95
7D
11.0%
1Y
3.4%
Jazz Pharmaceuticals
Market Cap: US$12.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$208.06
7D
3.4%
1Y
76.0%
Bristol-Myers Squibb
Market Cap: US$118.9b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$57.38
7D
-0.7%
1Y
14.6%
Immunocore Holdings
Market Cap: US$1.4b
Engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
IMCR
US$28.52
7D
-0.1%
1Y
-6.9%
Innoviva
Market Cap: US$1.7b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$22.99
7D
-1.6%
1Y
22.7%
Verrica Pharmaceuticals
Market Cap: US$107.7m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.36
7D
-6.8%
1Y
42.7%
Coherus Oncology
Market Cap: US$277.6m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.73
7D
-6.0%
1Y
69.6%
Zoetis
Market Cap: US$48.0b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$112.68
7D
-4.4%
1Y
-28.7%
ProQR Therapeutics
Market Cap: US$163.3m
A clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
PRQR
US$1.64
7D
10.1%
1Y
-8.9%
Prestige Consumer Healthcare
Market Cap: US$2.6b
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
PBH
US$55.31
7D
-5.1%
1Y
-33.3%
Harmony Biosciences Holdings
Market Cap: US$1.8b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
HRMY
US$32.59
7D
5.0%
1Y
8.8%
Tarsus Pharmaceuticals
Market Cap: US$2.7b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$64.57
7D
6.0%
1Y
34.5%